Costs and Trends in Utilization of Low-value Services among Older Adults with Commercial Insurance or Medicare Advantage

Medical Care

Volumn 55, Issue 11, 2017, Pages 931-939

  Carter, Elizabeth A ^a,b   Morin, Pamela E ^b   Lind, Keith D ^a  

^a AARP   (United States)

^b OPTUM   (United States)

Author keywords

administrative claims; commercial insurance; low value care; Medicare Advantage; older adults

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; COMMERCIAL PHENOMENA; CONTROLLED STUDY; FAINTNESS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INVASIVE PROCEDURE; KIDNEY ARTERY; LAMINECTOMY; MALE; MEDICARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CLINICAL PRACTICE; ECONOMICS; EVALUATION STUDY; FACTUAL DATABASE; HEALTH INSURANCE; HEALTH SERVICE; MIDDLE AGED; PATIENT ATTITUDE; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; MALE; MEDICAL OVERUSE; MEDICARE PART C; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 85031767130     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000809     Document Type: Article

References (46)

1. Centers for Medicare and Medicaid Services. National Health Expenditures 2014 Highlights. 2015.
2. Emanuel EJ, Fuchs VR. The perfect storm of overutilization. JAMA. 2008;299:2789-2791.
3. Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA. 1998;280:1000-1005.
4. ABIM Foundation Choosing Wisely Campaign. Available at: www. choosingwisely.org/. Accessed March 7, 2016.
5. Segal JB, Bridges JF, Chang HY, et al. Identifying possible indicators of systematic overuse of health care procedures with claims data. Med Care. 2014;52:157-163.
6. Schwartz AL, Landon BE, Elshaug AG, et al. Measuring low-value care in Medicare. JAMA Intern Med. 2014;174:1067-1076.
7. Rosenberg A, Agiro A, Gottlieb M, et al. Early trends among seven recommendations from the Choosing Wisely Campaign. JAMA Intern Med. 2015;175:1913-1920.
8. Charlesworth CJ, Meath TH, Schwartz AL, et al. Comparison of lowvalue care in medicaid vs. commercially insured populations. JAMA Intern Med. 2016;176:998-1004.
9. Reid RO, Rabideau B, Sood N. Low-value health care services in a commercially insured population. JAMA Intern Med. 2016;176: 1567-1571.
10. Colla CH, Morden NE, Sequist TD, et al. Choosing wisely: prevalence and correlates of low-value health care services in the United States. J Gen Intern Med. 2015;30:221-228.
11. Colla CH, Morden NE, Sequist TD, et al. Erratum to: Choosing Wisely: prevalence and correlates of low-value health care services in the United States. J Gen Intern Med. 2016;31:450.
12. Elshaug AG, McWilliams JM, Landon BE. The value of low-value lists. JAMA. 2013;309:775-776.
13. OptumLabs. OptumLabs and OptumLabs Data Warehouse (OLDW) Descriptions and Citation. Cambridge, MA: 2017. n.p. (PDF. Reproduced with permission from OptumLabs).
14. 2016 Annual report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. Board of Trustees 2016;Table V.B4:186. Available at: https://www.cms. gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ ReportsTrustFunds/Downloads/TR2016.pdf.
15. Smith J, Medalia C. Health Insurance Coverage in the United States: 2014. United States: Census Bureau; 2015.
16. Morden NE, Colla CH, Sequist TD, et al. Choosing wisely\-The politics and economics of labeling low-value services. N Engl J Med. 2014;370:589-592.
17. FDA. FDA public health notification: life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion. 2008.
18. Epstein NE. Complications due to the use of BMP/INFUSE in spine surgery: the evidence continues to mount. Surg Neurol Int. 2013;4 (suppl 5):S343-S352.
19. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Ann Intern Med. 2008;149:638-658.
20. Vesco KK,Whitlock EP, Eder M, et al. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the US Preventive Services Task Force. Ann Intern Med. 2011;155: 698-705. W216.
21. Lin K, Lipsitz R, Miller T, et al. Force USPST. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Ann Intern Med. 2008;149:192-199.
22. Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009;30:2631-2671.
23. Douglas AC, Wippold FJ, Broderick DF, et al. ACR Appropriateness Criteria Headache. Reston, VA: American College of Radiology; 2013.
24. Chou R, Fu R, Carrino JA, et al. Imaging strategies for low-back pain: systematic review and meta-analysis. Lancet. 2009;373:463-472.
25. Cornelius RS, Martin J, Wippold FJ 2nd, et al. ACR appropriateness criteria sinonasal disease. J Am Coll Radiol. 2013;10:241-246.
26. Joo HS, Wong J, Naik VN, et al. The value of screening preoperative chest x-rays: a systematic review. Can J Anaesth. 2005;52:568-574.
27. Qaseem A, Alguire P, Dallas P, et al. Appropriate use of screening and diagnostic tests to foster high-value, cost-conscious care. Ann Intern Med. 2012;156:147-149.
28. American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, Douglas PS, Garcia MJ, Haines DE, et al. J Am Coll Cardiol. 2011;57:1126-1166.
29. McConnell CT, Wippold FJ, Ray CE, et al. ACR Appropriateness Criteria Management of Vertebral Compression Fractures. Reston, VA: American College of Radiology; 2013.
30. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009;361:557-568.
31. Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med. 2009;361:569-579.
32. McCullough BJ, Comstock BA, Deyo RA, et al. Major medical outcomes with spinal augmentation vs conservative therapy. JAMA Intern Med. 2013;173:1514-1521.
33. Alternatives to hysterectomy in the management of leiomyomas. Washington, DC: American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin; no. 96. 2008.
34. Management of abnormal cervical cancer screening test results and cervical cancer precursors. Washington, DC: American College of Obstetricians and Gynecologists (ACOG); ACOG practice bulletin; no. 140. 2013.
35. Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13-22.
36. Wheatley K, Ives N, Gray R, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361: 1953-1962.
37. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45 (suppl S):S5-S67.
38. Chrastil J, Low JB, Whang PG, et al. Complications associated with the use of the recombinant human bone morphogenetic proteins for posterior interbody fusions of the lumbar spine. Spine (Phila Pa 1976). 2013;38: E1020-E1027.
39. US Food and Drug Administration. Recombinant human bone morphogenetic protein in cervical spine fusion. US Food and Drug Administration Public Health Notification. 2008. Available at: www.fda.gov/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedical Products/ucm079019.htm. Accessed September 20, 2016.
40. Gonzales R, Cattamanchi A. Changing clinician behavior when less is more. JAMA Intern Med. 2015;175:1921-1922.
41. Howard DH, Gross CP. Producing evidence to reduce low-value care. JAMA Intern Med. 2015;175:1893-1894.
42. Newhouse JP, Price M, Huang J, et al. Steps to reduce favorable risk selection in medicare advantage largely succeeded, boding well for health insurance exchanges. Health Aff (Millwood). 2012;31:2618-2628.
43. Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA. 2012;307:1513-1516.
44. Request for information regarding implementation of the merit-based incentive payment system, promotion of alternative payment models, and incentive payments for participation in eligible alternative payment models. Vol 80 (190): Federal Register; October 1, 2015:59102-59113.
45. Colla CH, Mainor AJ, Hargreaves C, et al. Interventions aimed at reducing use of low-value health services: a systematic review. Med Care Res Rev. 2016;74:507-550.
46. Shteynshlyuger A, Andriole GL. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. J Urol. 2011;185:828-832.